Alopecia areata and depression tend to co-occur; however, their temporal association has not been comprehensively investigated. The aim of this study was to examine the temporal association between alopecia areata and depression. The study included only cases with a comorbid presentation of alopecia areata and depression (n=1,936), extracted from the databases of the Clalit Health Services, Israel. Survival analyses were used to assess the cumulative probability of receiving alopecia areata as comorbid diagnosis in the years following depression, and vice versa, compared with the opposite trajectory. The results indicate that patients with alopecia areata had greater odds of subsequent depression within 2 years from alopecia areata diagnosis, and showed a steeper increase in cumulative probability of depression as time progressed (log-rank =336.38, p<0.001), compared with the opposite trajectory. All patients with alopecia areata had comorbid depression within 10 years of alopecia areata, compared with 70% of depression patients receiving diagnoses of comorbid alopecia areata within the same time-frame.

Key words: alopecia areata; depression; comorbidity: temporal presence.

Accepted Feb 11, 2022; Epub ahead of print Feb 11, 2022
Acta Derm Venereol 2022; 102: adv00669.
DOI: 10.2340/actadv.v102.1622
Corr: Dana Tzar Bitan, Department of Behavioral Sciences, Ariel University, IL-40700 Ariel, Israel. E-mail: danatz@ariel.ac.il

Alopecia areata (AA) is an autoimmune hair-loss disorder, which affects approximately 2% of the population, and is characterized by non-scarring, typically remitting, hair loss of varying degrees from the scalp and body (1). Many studies have demonstrated the psychological correlates of AA, which include anxiety (2), stress (3), and social and functional deficits (4). The disease has also been found to be highly correlated with depression (5), a psychiatric disorder characterized by lower mood, reduced energy, and functional and social withdrawal (6, 7). According to the WHO, depression is a leading cause of morbidity and mortality worldwide, and can be minimized by effective treatment (8). Studies assessing the effect of comorbid depression among patients with AA found that their co-occurrence was associated with impaired social and career-related functioning, sleep disruption, and even suicidal ideation (9, 10). Thus, the study of the mechanisms leading to this co-occurrence is of great empirical and clinical significance.

Studies attempting to delineate the trajectories leading from either AA to depression, or vice versa, have suggested bidirectional effects to account for this concurrence. It has been suggested that relapsing episodes of hair loss can provoke psychological distress through effects on self-image, subjective loss of control, and even loss of sense of self (11). On the other hand, both clinical and biological studies have demonstrated that stress, a well-recognized potentiator of depression, can independently trigger or exacerbate hair loss, largely through pro-inflammatory or neuroendocrine effects (12–15). Although these findings point to several potential causal trajectories, only a few studies have attempted to assess the temporal relation of AA and depression. In a study utilizing the National Health Insurance (NHI) database of Taiwan, Chu et al. (16) analysed 146 patients with both AA and depression, and reported that the onset of comorbid AA in patients first diagnosed with depression appeared in 54.1% of cases. However, the authors did not perform further analyses focusing on the temporal progression of the development of the second diagnosis. In a different, large-scale, retrospective population-based study in the UK, cohorts with either depression (n=405,339) or AA (n=6,861) were compared with respective reference cohorts to determine the risk of developing the second disorder (17). The authors reported that depression increased the risk of developing subsequent AA by 90%, whereas AA increased the risk of subsequent
depression by 34%. Nonetheless, the time between the onset of the first condition and the co-occurrence of the second condition was not evaluated.

The aim of this population-based study was to provide a detailed temporal characterization of the relationship between AA and depression. Cases of patients with comorbid AA and depression were extracted, and the time gap was calculated by extracting dates of both diagnoses. Cases were divided to belong either to AA followed by depression, or depression followed by AA. The odds of receiving the comorbid diagnosis of either AA or depression within the consecutive years following the onset of the first condition were then estimated. The study utilized the databases of the Clalit Health Services (CHS), a comprehensive data registry of the largest healthcare organization in Israel, which contains a highly validated registry of diagnoses.

**MATERIALS AND METHODS**

**Study design**

Data were extracted from the CHS database. The CHS is the largest healthcare service in Israel, covering medical care costs for the majority of the country’s population: 5 million citizens in Health Ministry reports of 2018 (18). The database harbours detailed administrative, as well as medical, data from a wide range of medical settings, including clinics, hospitals, specialists and pharmacies. Automated and manual validation is routinely performed to ensure updated and authentic data. The CHS database received external validation in a previous evaluation study (19) and was previously validated for both dermatological and psychiatric diagnoses (20–22). This study was approved by the institutional review board of CHS. Informed consent was waived, as strictly non-identifiable data were used.

**Study population**

Data regarding diagnoses and their time of registry were extracted in April 2020, employing the International Classification of Diseases (ICD-9) for identification of medical records (23). All AA diagnoses utilized were registered by board-certified dermatologists (code 704). Depression diagnoses were included only if registered by a board-certified psychiatrist or following hospital discharge. Diagnoses included Major Depressive Disorder (code 2962), Major Depressive Affective Disorder (codes 29620-29626, 29630-29626), Adjustment Reaction with Depressive Reaction (3090-3091), Depressive Type Psychosis (2980), and Neurotic Depression (3004). Socioeconomic status (SES) was obtained using the CHS index, calculated as an index score combining information from social services, and demographic variables, such as district and current address. Data extraction was performed from a database containing a total of 41,184 patients diagnosed with AA. From this database, 1,936 (4.7%) cases were identified as AA with comorbid depression diagnoses. These cases served as the sample for all reported analyses.

**Statistical analysis**

Demographic and clinical information was assessed with a $\chi^2$ test for categorical variables and a Student’s $t$-test for age. Cases were aggregated prior to statistical analyses to belong to either AA followed by depression, or depression followed by AA, through the dates and years of diagnoses. Cases of simultaneous presentation (within the same year) were excluded from the temporal analyses. Univariate logistic regressions were employed to assess the odds of receiving a comorbid diagnosis of either AA or depression in the years following the onset of the first condition. Estimated projections of the cumulative probability of receiving a diagnosis of either comorbid AA, or comorbid depression, were obtained using Kaplan–Meier analysis. The log-rank test was used to determine whether survival curves differed statistically between patients with AA who presented with later co-occurring depression, or individuals with depression who presented with later co-occurring AA. Statistical analysis was performed with SPSS software, version 25 (SPSS, Chicago, IL, USA).

**RESULTS**

A visual illustration of the distribution of comorbid cases (AA followed by depression, depression followed by AA, and simultaneous diagnosis) is shown in Fig. 1.

As can be seen, of the 1,936 patients with comorbid AA and depression, 1,211 (62.6%) were first diagnosed with depression and later developed AA; 591 patients (30.5%) were first diagnosed with AA and later developed depression; and 134 patients (6.9%) received the 2 diagnoses within the same year. Demographic characteristics of the 2 groups (depression with subsequent AA, AA with subsequent depression) are shown in Table I.

As can be seen, patients with depression and subsequent AA were older (mean ± standard deviation (SD) 52.26 ± 14.93 years) in comparison with patients with AA and subsequent depression (46.95 ± 15.53 years), $p<0.001$. Higher proportions of males were found among patients with depression and subsequent AA compared with patients with AA and subsequent depression (41.0% vs 45.9%, respectively, $p=0.05$). In addition, patients with depression and subsequent AA had a higher SES (medium-high), in comparison with patients with AA and subsequent depression (61.4% vs 56.0, $p<0.05$). Married cases accounted for 45.2% of patients with depression.

**Fig. 1.** Graphical illustration of prevalence of time precedence ($n = 1,936$). AA: alopecia areata.
and subsequent AA (n=547), and 44.0% of patients with AA and subsequent depression (n=260), with no significant differences between the groups. Smoking rates were also similar, with 670 (55.3%) and 319 (54.0%), respectively. Rates of obesity, diabetes, and mean body mass index (BMI) values were similar across groups. Finally, the time from first diagnosis was different between groups, with time for depression followed by AA being longer (8.37 ± 10.9 years) compared with time for AA followed by depression (4.02 ± 2.44 years), p<0.001.

The estimated cumulative probabilities of AA onset subsequent to depression or depression onset subsequent to AA are shown in Fig. 2.

As can be seen, survival analysis indicates that patients with AA had greater odds of developing depression within the first 2 years after the onset of AA compared with the odds of patients with depression developing AA.

Moreover, patients with initial AA presented a more rapid increase in the cumulative probability of being diagnosed with depression over time (log-rank test=336.38, p<0.001), with all cases of comorbid depression developing within 10 years of initial AA. In contrast, the cumulative probability of being diagnosed with AA subsequent to depression manifested as a more moderate incline, with only 70% of patients with depression developing comorbid AA by the end of the first decade.

Table II presents the odds of receiving a comorbid diagnosis after initial AA or depression, at different time points since initial diagnosis. As can be seen, the odds of developing AA subsequent to depression were higher in the time-period 2–4 years after depression diagnosis, odds ratio (OR) 1.33, 95% confidence interval (95% CI) (1.00–1.77), p<0.05, compared with the odds of after 0–2 years. After 2–4 years, the odds of AA onset subsequent to depression increased progressively until reaching a maximum of 8 years or more since diagnosis of depression (OR 15.89, 95% CI 10.39–24.31), p<0.05. In contrast, the odds of depression onset after AA diagnosis were lower in the 2–4-year period following the AA diagnosis, OR 0.74 95% CI (0.56–0.99), p<0.05, with the odds gradually decreasing over time.

**DISCUSSION**

The initial examination of patients with dual diagnoses demonstrated that the majority of patients (62.55%) were first diagnosed with depression and only later with AA. However, a closer analysis of progression to second diagnosis, revealed differences in temporal patterns between the groups. Survival and regression analyses indicated that onset of depression after AA occurred at a faster rate than the onset of AA after depression, with the highest odds of depression onset manifesting within the first few years following the initial AA diagnosis. Overall, all cases of AA received a comorbid diagnosis of depression within the 10-year period after diagnosis of AA. On the other hand, the onset of comorbid AA after initial depression was far slower, and occurred more than 20 years after the initial diagnosis. Only 70% of those with initial depression showed a comorbid presentation of AA within the first decade, with odds increasing over time. These findings indicate a highly intricate temporal relationship between depression and AA. Although a bidirectional relationship between AA and depression exists, AA may manifest as a more proximal risk factor for the development of subsequent depression, whereas depression may serve as a more distal risk factor.

Previous studies assessing the nature of directional patterns of depression and AA
have reported similar patterns to those reported in the current study. Chu et al. (16) similarly found that, in the case of comorbidity, depression occurred earlier than AA in the majority of cases (54%). In another large-scale cohort study, Vallerand et al. (17) found that 662 individuals in the depression cohort subsequently developed AA, whereas only 513 patients in the AA cohort were subsequently diagnosed with depression. These results correspond to the earlier findings reported in this study, which indicate that 62% of the current sample was first diagnosed with depression and later developed AA. Nonetheless, as these studies did not include an analysis of the time intervals between the first and second diagnoses, they typically portray a partial picture of the pattern of temporal association.

Although Chu et al. (16) did not perform a temporal analysis in the form of a continuous follow-up from the time of the first disorder until the development of the second, the authors reported the median time interval between the first and second diagnoses within each group. Their report indicated that, although 54.1% of patients had pre-existing depression before AA, the onset of depression after having AA occurred faster in approximately 30% of cases. In a study conducted in Taiwan (24), the authors assessed the bidirectional association between AA and depression among probands and unaffected siblings compared with controls. The authors found that the risk of developing depression among patients with AA was 8.22-fold greater than controls, approximately 5 times higher than depressed patients developing AA (1.66-fold higher risk compared with controls). Although the findings of the current study suggest that comorbid cases are more frequently diagnosed with depression followed by AA, this comparison is restricted only to the cohort of comorbid cases. Thus, it is possible that issues related to the overall prevalence of the 2 conditions, the age of onset, and other aetiological factors, are responsible for this differential pattern of presentation. Interestingly, the authors found that unaffected siblings of patients with AA had a 2.55-fold risk of developing depression compared with controls, vs unaffected siblings of patients with depression with only a 1.64-fold increased risk of developing AA. These findings strengthen the idea that, while a bidirectional genetic predisposition exists, it appears to be more profound in the direction of AA predisposing to subsequent depression. These reports provide additional support for our later findings, indicating that patients may be at more immediate risk of developing depression after AA than vice versa.

The first 2 years after diagnosis of AA were found to be the most likely time-period for developing depression. Given the extensive evidence for AA patients report in self-image, relationships, and career, it is plausible that depression develops as a result of the negative psychosocial effects of AA, which might manifest within the first few years after its onset. In a study of 162 patients with AA, patients stressed the loss of self-confidence, fear of socializing, poor work performance, and feeling of helplessness (25). Other studies have reported a high correlation with psychiatric diseases and even suicidal ideation (10, 26). A meta-analysis of 21 studies worldwide, representing 2,530 adult patients, showed that patients with AA experience significantly impaired health-related quality of life, especially in mental health domains, as well as concurring depression and anxiety, which further reduced quality of life (27). An alternative explanation can be found in immunological findings, which indicate high levels of type 17 and type 2 immune response cytokines, including IL-17A, IL-21, IL-23 and IL-17F and IL-33, IL-3, IL17E(IL-25), in patients with AA. This study also reported a correlation of IL-22 and IL-17E with depression, suggesting an immunological mechanism for the development of depression (28). Finally, depression has been shown to often be a chronic, recurrent condition, with many patients not fully recovering for years after onset (29). This could suggest an ongoing immune dysregulation may contribute to the late occurring AA comorbidity. Thus, the current study may support the idea of molecular pathways that are potentially involved in the pathogenesis of depression subsequent to AA. Such explanatory hypotheses require further evaluation.

This study has several strengths and limitations. The study presents a novel analysis of the temporal relationship between AA and depression, demonstrating the intricate and complex nature of the bidirectional relationship on a relatively large sample of patients with the co-occurring conditions. Clinicians should be mindful of the specific time-periods that may lead to increased risk of comorbid depression, and screen for potential distress during this time-period. Furthermore, studies indicate that patients with AA with comorbid depression tend to have exacerbations of dermatological disease, poor disease management, and increased suicidal ideation (30). The knowledge of the time interval in which probability is high for such co-occurrence may allow dermatologists to provide early intervention and prevent

Table II. Multivariate logistic regression analysis of the probabilities of alopecia areata (AA) onset subsequent to depression and depression onset subsequent to AA, stratified by time since first diagnosis

| Time since first diagnosis | Depression followed by AA | AA followed by depression |
|---------------------------|---------------------------|---------------------------|
| n (%) OR (95% CI) | p-value n (%) OR (95% CI) | p-value |
| 0–2 years | 190 (15.7) 1 | 200 (33.8) 1 | 0.05 (0.55–0.99) < 0.001 |
| 2–4 years | 208 (17.2) 1.33 (1.00–1.77) | < 0.05 164 (27.7) 0.74 (0.56–0.99) | < 0.05 |
| 4–6 years | 186 (15.4) 1.71 (1.26–2.33) | < 0.01 114 (19.3) 0.58 (0.42–0.79) | < 0.01 |
| 6–8 years | 189 (15.6) 2.36 (1.71–3.27) | < 0.001 84 (14.2) 0.42 (0.30–0.58) | < 0.001 |
| ≥ 8 years | 438 (36.2) 15.89 (10.39–24.31) | < 0.001 29 (4.9) 0.06 (0.04–0.09) | < 0.001 |

OR: odds ratio; 95% CI: 95% confidence interval. Period 0–2 years served as the reference group for the multivariate analyses.
further dermatological and psychological complications. Empirically, the results of the current study could serve as an infrastructure for future studies assessing the etiology and phenomenology of depression and AA comorbidity. The analyses in demographic characteristics indicated that there are some differences between individuals who develop depression followed by subsequent AA, and individuals who develop AA followed by subsequent depression. Future studies should explore potential pathways leading to these differences. Several limitations should also be acknowledged. Specific parameters such as subtype, severity, or treatment of AA and depression were not assessed in this study. Further studies should comprehensively elucidate the pathogenesis underlying the disorders while testing the association within the different subtypes. As cultural factors might be associated with the results reported in this study, future studies should further assess the cross-cultural validity of the reported findings. Taken together, the results prompt improved clinical interventions and provide further grounds for additional investigative research.

ACKNOWLEDGEMENTS

This study was supported by an unrestricted grant from Pfizer Pharmaceuticals Israel (grant number 55983831).

Conflicts of interest. DTB received a research grant from Pfizer and from the American Psychological Foundation. AC received research grants from Janssen, Novartis, AbbVie, Janssen and Sanoﬁ. He also served as a consultant, advisor, or speaker to AbbVie, Amgen, Boehringer Ingelheim, Dexcel pharma, Janssen, Kamedis, Lilly, Neopharm, Novartis, Perrigo, Pfizer, Rafa, Samsung Bioepis, Sanofi, Sirbal, and Taro.

REFERENCES

1. Strazulla LC, Wang EHC, Avila L, Lo Sicco K, Brinster N, Christiano AM, Shapiro J. Alopecia areata: disease characteristics, clinical evaluation, and new perspectives on pathogenesis. J Am Acad Dermatol 2018; 78: 1–12.
2. Mulinari-Brenner F. Psychosomatic aspects of alopecia areata. Clin Dermatol 2018; 36: 709–713.
3. Pratt CH, King Jr. LE, Messenger AG, Christiano AM, Sundberg JP. Alopecia areata. Nat Rev Dis Primers 2017; 3: 1–17.
4. Tucker P. Bald is beautiful?: the psychosocial impact of alopecia areata. J Health Psycho 2009; 14: 142–151.
5. Okhovat JP, Marks DH, Manatis-Lornell A, Hagigeorges D, Locascio JJ, Senna MM. Association between alopecia areata, anxiety, and depression: a systematic review and meta-analysis. J Am Acad Dermatol 2019 Jun 1 [Epub ahead of print].
6. McCarter T. Depression overview. Am Health Drug Benefits 2008; 1: 44–51.
7. Katz SJ, Conway CC, Hammen CL, Brennan PA, Najman JM. Childhood social withdrawal, interpersonal impairment, and young adult depression: a mediational model. J Abnorm Child Psychol 2011; 39: 1227–1238.
8. WHO. The global burden of disease: 2004 update. Geneva: World Health Organization; 2008.
9. Baghestani S, Zare S, Seddigh SH. Severity of depression and anxiety in patients with alopecia areata in Bandar Abbas, Iran. Dermatol Reports 2015; 7: 6063.
10. Velez-Muniz RDC, Peralta-Pedrero ML, Jurado-Santa Cruz F, Morales-Sanchez MA. Psychological profile and quality of life of patients with alopecia areata. Skin Appendage Disord 2019; 5: 293–298.
11. Hunt N. The psychological impact of alopecia. BMJ 2005; 331: 951–953.
12. Gupta MA, Gupta AK, Watteel GN. Stress and alopecia areata: a psychodermatologic study. Acta Derm Venereol 1997; 77: 296–298.
13. Manolache L, Bena V. Stress in patients with alopecia areata and vitiligo. J Eur Acad Dermatol Venereol 2007; 21: 921–928.
14. Simakou T, Butcher JP, Reid S, Henriquez FL. Alopecia areata: a multifactorial autoimmune condition. J Autoimmun 2019; 98: 74–85.
15. Thom E. Stress and the hair growth cycle: cortisol-induced hair growth disruption. J Drugs Dermatol 2016; 15: 1001–1004.
16. Chu SY, Chen YJ, Tseng WC, Lin MW, Chen TJ, Hwang CY. Psychiatric comorbidities in patients with alopecia areata in Taiwan: a case–control study. Br J Dermatol 2012; 166: 525–531.
17. Vallerand IA, Lewinson RT, Parsons LM, Hardin J, Haber RM, Lowerison MW, et al. Assessment of a bidirectional association between major depressive disorder and alopecia areata. JAMA Dermatol 2019; 155: 475–479.
18. Ministry of Health (II). Annual report of healthcare-providing companies for 2018. [accessed 2020 March 27]. Available from: https://www.health.gov.il/PublicationsFiles/doc-Hashvaatui2018.pdf.
19. Rennert G, Peterburg Y. Prevalence of selected chronic diseases in Israel. Isr Med Assoc J 2001; 3: 404–408.
20. Tzur Bitan D, Berzin D, Cohen AD. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study. J Eur Acad Dermatol Venereol 2020; 34: 574–579.
21. Tzur Bitan D, Berzin D, Cohen A. Hidradenitis suppurativa and bipolar disorders: a population-based study. Dermatology 2020; 236: 298–304.
22. Tzur Bitan D, Berzin D, Cohen A. The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study. Arch Dermatol Res 2020; 313: 33–39.
23. World Health Organization (WHO). International classification of diseases, Ninth revision. Geneva: WHO; 1978.
24. Dai YX, Tai YH, Chen CC, Chang YT, Chen TJ, Chen MH. Bidirectional association between alopecia areata and major depressive disorder among probands and unaffected siblings: a nationwide population-based study. J Am Acad Dermatol 2020; 82: 1131–1137.
25. Hunt N, McHale SUE. Reported experiences of persons with alopecia areata. J Loss Trauma 2004; 10: 33–50.
26. Sinclair RD. Alopecia areata and suicide of children. Med Aust 2014; 200: 145.
27. Rencz F, Gulácsi L, Péntek M, Wikonkál N, Baji P, Brodszky V. Alopecia areata and health-related quality of life: a systematic review and meta-analysis. Br J Dermatol 2016; 175: 561–571.
28. Bain KA, McDonald E, Moffat F, Tutino M, Castelino M, Barton A, et al. Alopecia areata is characterized by dysregulation in systemic type 17 and type 2 cytokines, which may contribute to disease-associated psychological morbidity. Br J Dermatol 2020; 182: 130–137.
29. Keller M. Depression: a long-term illness. Br J Psychiatry 1994; 165: 9–15.
30. Rodgers AR. Why finding a treatment for alopecia is important: a multifaceted perspective. J Investig Dermatol Symp Proc 2018; 19: S51–S53.